DMAC vs DSGN

DiaMedica Therapeutics Inc. vs Design Therapeutics, Inc. — Valuation Comparison 2026

DMAC

Pharmaceutical Preparations
DiaMedica Therapeutics Inc.
Quality
4.7
out of 10
Value Trap
18
SAFE
Price
$5.99
Last close
Models
7/13
Active
VS

DSGN

Pharmaceutical Preparations
Design Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
24
SAFE
Price
$10.48
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType DMAC Fair ValueDMAC Upside DSGN Fair ValueDSGN Upside
Bayesian DCF Intrinsic $1.55 -74.1% $3.02 -71.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.45 -92.5% $0.57 -94.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DMAC vs DSGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DMAC vs DSGN — Which Stock Is More Undervalued?

DMAC scores higher with a 4.7/10 quality rating vs DSGN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing DiaMedica Therapeutics Inc. (DMAC) and Design Therapeutics, Inc. (DSGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DMAC currently trades at $5.99 with a QOC of 4.7/10, while DSGN trades at $10.48 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).